Holen Sie sich die Stockscreener-App
5.25
4.55%
-0.25
Schlusskurs vom Vortag:
$5.50
Offen:
$5.51
24-Stunden-Volumen:
2.36M
Relative Volume:
0.39
Marktkapitalisierung:
$1.44B
Einnahmen:
$8.10M
Nettoeinkommen (Verlust:
$-92.72M
KGV:
-14.70
EPS:
-0.3571
Netto-Cashflow:
$-82.52M
1W Leistung:
-9.95%
1M Leistung:
+29.31%
6M Leistung:
+116.05%
1J Leistung:
+183.78%
1-Tages-Spanne:
$5.16
$5.53
1-Wochen-Bereich:
$5.16
$5.8116
52-Wochen-Spanne:
$1.05
$6.02
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Firmenname
Taysha Gene Therapies Inc
Sektor
Branche
Telefon
(214) 612-0000
Adresse
3000 PEGASUS PARK DRIVE, DALLAS
Vergleichen Sie TSHA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
5.25 | 1.51B | 8.10M | -92.72M | -82.52M | -0.3571 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Raymond James | Strong Buy |
| 2025-07-11 | Eingeleitet | BofA Securities | Buy |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-04-09 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-01 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-03-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-03-01 | Eingeleitet | Wells Fargo | Overweight |
| 2022-02-18 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-16 | Eingeleitet | Guggenheim | Buy |
| 2021-07-16 | Eingeleitet | Needham | Buy |
| 2021-06-24 | Eingeleitet | Truist | Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-06-09 | Eingeleitet | Wedbush | Outperform |
| 2021-06-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Fortgesetzt | Jefferies | Buy |
| 2021-02-24 | Eingeleitet | William Blair | Outperform |
| 2021-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2020-10-19 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-19 | Eingeleitet | Goldman | Buy |
| 2020-10-19 | Eingeleitet | Jefferies | Buy |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Taysha Gene Therapies Inc Aktie (TSHA) Neueste Nachrichten
Taysha Gene Therapies (NASDAQ:TSHA) Cut to "Sell" at Wall Street Zen - MarketBeat
Aug Highlights: Can Taysha Gene Therapies Inc stock rebound after recent weaknessIPO Watch & Precise Buy Zone Tips - moha.gov.vn
Taysha Gene Therapies (NASDAQ:TSHA) Shares Down 4.8%What's Next? - MarketBeat
Rice Hall James & Associates LLC Buys New Holdings in Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap UpHere's Why - MarketBeat
Taysha Gene Therapies stock hits 52-week high at $5.98 By Investing.com - Investing.com Nigeria
Taysha Gene Therapies stock hits 52-week high at $5.98 - Investing.com
Taysha Gene Therapies (NASDAQ:TSHA) Reaches New 1-Year HighHere's What Happened - MarketBeat
Does Taysha Gene Therapies Still Offer Value After a 196.8% Year to Date Surge? - Yahoo Finance
Is FDA Breakthrough Status For TSHA-102 Reshaping The Investment Case For Taysha Gene Therapies (TSHA)? - Yahoo Finance
Taysha Gene Therapies (TSHA): Revisiting Valuation After Breakthrough Rett Data and Bullish Analyst Upgrades - Yahoo Finance
Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Continues to Advance Rett Syndrome Program - Insider Monkey
Is Taysha Gene Therapies Inc. stock recession proofQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - Улправда
How analysts rate Taysha Gene Therapies Inc. stock todayBull Run & Weekly Stock Breakout Alerts - Улправда
Earnings Report: Is Taysha Gene Therapies Inc. stock recession proofWeekly Stock Analysis & Risk Controlled Stock Alerts - Улправда
Breakouts Watch: Is Taysha Gene Therapies Inc. stock recession proof2025 Trade Ideas & Free Fast Gain Swing Trade Alerts - Улправда
Can Taysha Gene Therapies Inc. stock beat analyst upgradesPortfolio Performance Summary & Growth Focused Stock Pick Reports - DonanımHaber
Can Taysha Gene Therapies Inc. stock rebound after recent weaknessQuarterly Trade Summary & Free Growth Oriented Trading Recommendations - DonanımHaber
Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock By Investing.com - Investing.com Canada
Taysha Gene Therapies (NASDAQ:TSHA) Hits New 1-Year HighTime to Buy? - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Rating Increased to Hold at Wall Street Zen - MarketBeat
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
1,203,941 Shares in Taysha Gene Therapies, Inc. $TSHA Purchased by Stempoint Capital LP - MarketBeat
B Group Inc. Buys 545,000 Shares of Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Taysha Gene Therapies stock hits 52-week high at 5.51 USD - Investing.com
Taysha Gene Therapies stock hits 52-week high at 5.51 USD By Investing.com - Investing.com South Africa
200,000 Shares in Taysha Gene Therapies, Inc. $TSHA Bought by Affinity Asset Advisors LLC - MarketBeat
Taysha Gene Therapies Grants Stock Options to New Employees as Part of Inducement Plan - Quiver Quantitative
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Can Taysha Gene Therapies Stock Hold Up When Markets Turn? - Trefis
Taysha Gene Therapies upgraded at Goldman Sachs on advancing Rett syndrome asset - MSN
Would You Still Hold Taysha Gene Therapies Stock If It Fell 30%? - Trefis
Taysha Gene Therapies (TSHA) Upgraded to Buy by Goldman Sachs - GuruFocus
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 7%Still a Buy? - MarketBeat
Taysha Gene Therapies (TSHA) Receives Buy Rating from Goldman Sa - GuruFocus
Taysha Gene Therapies (NASDAQ:TSHA) Shares Down 6.5% on Insider Selling - MarketBeat
How Taysha Gene Therapies Inc. stock reacts to oil prices2025 EndofYear Setup & Technical Confirmation Alerts - Newser
Sukumar Nagendran Sells 110,125 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock - MarketBeat
Taysha Gene Therapies Insider Sold Shares Worth $1,695,906, According to a Recent SEC Filing - marketscreener.com
Sukumar Nagendran Sells 260,047 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock - MarketBeat
Nagendran Sukumar sells Taysha gene therapies (TSHA) shares for $1.69m - Investing.com Canada
TSHA FY2026 EPS Forecast Raised by Cantor Fitzgerald - MarketBeat
Jefferies Financial Group Inc. Acquires 10,068,479 Shares of Taysha Gene Therapies, Inc. $TSHA - MarketBeat
SG Americas Securities LLC Makes New $1.14 Million Investment in Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Will breakout in Taysha Gene Therapies Inc. lead to full recoveryQuarterly Performance Summary & Low Risk High Win Rate Stock Picks - newser.com
Using Bollinger Bands to evaluate Taysha Gene Therapies Inc.Portfolio Return Report & Growth-Oriented Investment Plans - newser.com
Finanzdaten der Taysha Gene Therapies Inc-Aktie (TSHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Taysha Gene Therapies Inc-Aktie (TSHA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nagendran Sukumar | President and Head of R&D |
Nov 28 '25 |
Option Exercise |
1.07 |
110,125 |
117,363 |
1,116,564 |
| Nagendran Sukumar | President and Head of R&D |
Dec 01 '25 |
Sale |
4.51 |
260,047 |
1,172,812 |
1,006,439 |
| Nagendran Sukumar | President and Head of R&D |
Nov 28 '25 |
Sale |
4.75 |
110,125 |
523,094 |
1,006,439 |
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):